RADIOPHARM THERANOSTICS LTD (RADX) Forecast, Price Target & Analyst Ratings

NASDAQ:RADX

Current stock price

4.64 USD
-0.06 (-1.28%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RADIOPHARM THERANOSTICS LTD (RADX).

Forecast Snapshot

Consensus Price Target

Price Target
$5.17
+ 11.49% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-A$3.16
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$5.17
Upside
+ 11.49%
From current price of $4.64 to mean target of $5.17, Based on 6 analyst forecasts
Low
$5.04
Median
$5.17
High
$5.41

Price Target Revisions

1 Month
-3.60%
3 Months
8.09%

Price Target Summary

6 Wall Street analysts provided a forecast for the next 12 months for RADX. The average price target is 5.17 USD. This implies a price increase of 11.49% is expected in the next year compared to the current price of 4.64.
The average price target has been revised upward by 8.09% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

RADX Current Analyst RatingRADX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

RADX Historical Analyst RatingsRADX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
RADX was analyzed by 6 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about RADX.
In the previous month the buy percentage consensus was at a similar level.
RADX was analyzed by 6 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-12-16B. Riley SecuritiesReiterate Buy -> Buy
2025-11-26B. Riley SecuritiesMaintains Buy -> Buy
2025-07-21Brookline CapitalInitiate Buy
2025-05-01Maxim GroupInitiate Buy
2025-03-12B. Riley SecuritiesInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-A$3.16
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
0.00%
Number of Analysts
2

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
RADX revenue by date.RADX revenue by date.
292.4K299.2K
2.33%		3.633M
1,114.37%
-100.00%		9.323M51.455M
451.91%		125.06M
143.05%		194.33M
55.39%		322.28M
65.84%		518.99M
61.04%		719.09M
38.56%
EBITDA
YoY % growth
RADX ebitda by date.RADX ebitda by date.
N/A
-29.94%		N/A
-79.58%		N/A
2.36%		-40.326M
0.68%		-24.107M
40.22%		4.949M
120.53%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
RADX ebit by date.RADX ebit by date.
-34.23M
-71.87%		-37.123M
-8.45%		-33.753M
9.08%		-83.974M
-148.79%		-84.176M
-0.24%		-36.747M
56.35%		4.873M
113.26%		66.192M
1,258.34%		181.66M
174.44%		354.14M
94.95%		516.06M
45.72%
Operating Margin
RADX operating margin by date.RADX operating margin by date.
-11,706.53%-12,407.55%-928.95%N/A-902.88%-71.42%3.90%34.06%56.37%68.24%71.77%
EPS
YoY % growth
RADX eps by date.RADX eps by date.
N/A
22.99%		N/A
20.65%		N/A
70.87%		-6.79
-10.26%		-6.00
11.63%		-3.00
50.00%		3.41
213.68%		6.34
86.11%		9.78
54.23%		19.06
94.84%		N/A

All data in AUD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-3.16-3.16-3.16-3.16
Revenue
Q2Q % growth
-100.00%
-100.00%
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-26.908M
-57.68%		-29.691M
-51.71%		-31.481M
-130.01%		-33.28M
-134.66%

All data in AUD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RADX Yearly Revenue VS EstimatesRADX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
RADX Yearly EPS VS EstimatesRADX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20 -30

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
14.80%
EPS Next 5 Year
24.83%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
123.94%
Revenue Next 5 Year
111.59%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
28.13%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

RADIOPHARM THERANOSTICS LTD / RADX Forecast FAQ

What do analysts expect the price target to be for RADIOPHARM THERANOSTICS LTD (RADX)?

6 analysts have analysed RADX and the average price target is 5.17 USD. This implies a price increase of 11.49% is expected in the next year compared to the current price of 4.64.

What are the consensus estimates for RADX stock next earnings?

The consensus EPS estimate for the next earnings of RADIOPHARM THERANOSTICS LTD (RADX) is -3.16 USD and the consensus revenue estimate is 0 USD.

Can you provide the consensus rating for RADIOPHARM THERANOSTICS LTD stock?

The consensus rating for RADIOPHARM THERANOSTICS LTD (RADX) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.